Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: Results from the SENTRY surveillance program (2010-2013)

Diagnostic Microbiology and Infectious Disease

Volumn 83, Issue 2, 2015, Pages 183-186

  Sader, Helio S ^a   Castanheira, Mariana ^a   Flamm, Robert K ^a   Mendes, Rodrigo E ^a   Farrell, David J ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Beta lactamases; Carbapenem resistance; KPC; VIM

Indexed keywords

AMIKACIN; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; COLISTIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER CLOACAE; EUROPE; GREECE; IN VITRO STUDY; ITALY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLAND; PRIORITY JOURNAL; ROMANIA; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; DNA SEQUENCE; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; EPIDEMIOLOGICAL MONITORING; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIPLEX POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EPIDEMIOLOGICAL MONITORING; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MULTIPLEX POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84941316706     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.06.011     Document Type: Article

References (28)

1. Brust K., Evans A., Plemmons R. Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review. J Antimicrob Chemother 2014, 69:2606-2610.
2. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., Jones R.N. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52:570-573.
3. Castanheira M., Mendes R.E., Woosley L.N., Jones R.N. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09). J Antimicrob Chemother 2011, 66:1409-1411.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 25th informational supplement (M100-S25) 2015, CLSI, Wayne, PA.
5. ECDC Antimicrobial Resistance Surveillance in Europe 2013 Available at, [Accessed June 9, 2015]. http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf.
6. Edelstein M.V., Skleenova E.N., Shevchenko O.V., D'Souza J.W., Tapalski D.V., Azizov I.S., et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013, 13:867-876.
7. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0 Available at, [Accessed January 2015]. http://www.eucast.org/clinical_breakpoints/.
8. Eurosurveillance editorial team ECDC publishes the annual epidemiological report 2012. Euro Surveill 2013, 18:20418.
9. Giani T., Pini B., Arena F., Conte V., Bracco S., Migliavacca R., et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill 2013, 18.
10. Glasner C., Albiger B., Buist G., Tambic Andrasevic A., Canton R., Carmeli Y., et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013, 18.
11. Gupta N., Limbago B.M., Patel J.B., Kallen A.J. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011, 53:60-67.
12. Hirsch E.B., Tam V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010, 65:1119-1125.
13. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008, 62:895-904.
14. Magiorakos A.P., Suetens C., Monnet D.L., Gagliotti C., Heuer O.E., Group E.A.-N.C., et al. The rise of carbapenem resistance in Europe: just the tip of the iceberg?. Antimicrob Resist Infect Control 2013, 2:6.
15. Miyakis S., Pefanis A., Tsakris A. The challenges of antimicrobial drug resistance in Greece. Clin Infect Dis 2011, 53:177-184.
16. Munoz-Price L.S., Poirel L., Bonomo R.A., Schwaber M.J., Daikos G.L., Cormican M., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013, 13:785-796.
17. Retamar P., Portillo M.M., Lopez-Prieto M.D., Rodriguez-Lopez F., de Cueto M., Garcia M.V., et al. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis. Antimicrob Agents Chemother 2012, 56:472-478.
18. Sader H.S., Flamm R.K., Jones R.N. Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). Diagn Microbiol Infect Dis 2013, 76:217-221.
19. Stein G.E., Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis 2013, 75:331-336.
20. Swaminathan M., Sharma S., Poliansky Blash S., Patel G., Banach D.B., Phillips M., et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 2013, 34:809-817.
21. Tavares C.P., Pereira P.S., Marques E.A., Faria C., de Souza M.D., de Almeida R., et al. Molecular epidemiology of KPC-2-producing Enterobacteriaceae (non-Klebsiella pneumoniae) isolated from Brazil. Diagn Microbiol Infect Dis 2015, 82:326-330.
22. Tygacil® Package Insert Tygacil® EPAR Product Information, United Kingdom Available at, [Accessed October 22, 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000644/WC500044508.pdf.
23. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., Tassios P.T., Daikos G.L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707.
24. van Duin D., Kaye K.S., Neuner E.A., Bonomo R.A. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis 2013, 75:115-120.
25. Vasoo S., Barreto J.N., Tosh P.K. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc 2015, 90:395-403.
26. Xu Y., Gu B., Huang M., Liu H., Xu T., Xia W., et al. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia. J Thorac Dis 2015, 7:376-385.
27. Yahav D., Lador A., Paul M., Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011, 66:1963-1971.
28. Zavascki A.P., Bulitta J.B., Landersdorfer C.B. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 2013, 11:1333-1353.